Diurnal Variations in Steady-state Plasma Concentrations of Valproic Acid in Epileptic Patients
Tóm tắt
Patients on long term valproate treatment exhibit unusual fluctuations in steady-state plasma levels of valproic acid. In order to delineate the underlying mechanisms of these fluctuations, 2 studies were undertaken. In the oral study, 6 epileptic patients received enteric-coated sodium valproate tablets (on a bid regimen for at least 1 month) and plasma levels were monitored on an hourly basis during 24 hours. In the intravenous study, 5 patients received first an intravenous bolus dose (800mg) of sodium valproate followed a week later by a combination intravenous loading dose/constant rate infusion for 36 hours. Plasma valproic acid concentrations were monitored hourly during the infusion study. In the oral study, valproic acid concentrations in all subjects continued to decay for 5 to 6 hours following the 8pm dose. The mean fluctuation in concentrations during 24 hours was 112.8 ± 31.6%. Consecutive fasting levels were not reproducible. In the intravenous study, small but significant oscillations were present at steady-state; fluctuations ranged from 22 to 34%. However, no circadian rhythm was apparent. On the basis of these findings, it appears that the value of a single fasting sample during therapeutic monitoring of valproic acid is questionable. For an accurate evaluation of valproic acid plasma levels, an average concentration based upon several daily determinations should be performed.
Tài liệu tham khảo
Baruzzi, A.; Bordo, B.; Bossi, L.; Castelli, D.; Gerna, M.; Tognoni, G. and Zagnoni, P.: Plasma levels of di-n-propylacetate and clonazepam in epileptic patients. International Journal of Clinical Pharmacology 15: 403–408 (1977).
Bruni, J.; Wilder, B.J.; Willmore, L.J.; Perchalski, R.J. and Villareal, H.J.: Steady-state kinetics of valproic acid in epileptic patients. Clinical Pharmacology and Therapeutics 24: 324–332 (1978a).
Bruni, J.L.; Wilder, B.J.; Willmore, L.J.; Villareal, H.J.; Thomas, M. and Crawford, L.E.M.: Clinical efficacy of valproic acid in relation to plasma levels. Journal Canadien des Sciences Neurologiques 5: 385–397 (1978b).
Cochet, B.: Influence de 1a nourriture sur la biodisponibilite des medicaments. Medecin et Hygiene 37: 969–972 (1979).
Fröscher, W.; Schulz, H.V. and Guller, R.: Valproinsäure in der Behandlung der Epilepsien unter besonderer Beruchsichtigung des Serumspiegels. Fortschritte der Neurologie Psychiatrie und ihrer Grenzgebiete. Ubersichten und Forschungsergebnisse 46: 327–341 (1978).
Gibaldi, M. and Perrier, D.: Multicompartment models: in Pharmacokinetics, pp.45–95 (Marcel Dekker, New York 1975).
Gram, L.; Flachs, H.; Wurtz-Jorgensen, A.; Parnas, S. and Andersen, B.: Sodium valproate. Relationship between serum levels and therapeutic effect in antiepileptic therapy; in Johan-nessen et al. (Eds) Advances in Drug Monitoring, pp.247–252 (Raven Press, New York 1980).
Henriksen, D. and Johannessen, S.I.: Clinical observations of dipropyl-acetate in children. An evaluation of therapeutic serum levels in antiepileptic therapy; in Johannessen et al. (Eds) Advances in Antiepileptic Drugs Monitoring, pp.253–261 (Raven Press, New York 1980).
Johannessen, S.I.: Preliminary observations on valproic acid kinetics in patients with epilepsy. Arzneimittel-Forschung 1: 1083–1088 (1977).
Klotz, U.: Pharmacokinetic studies with valproic acid in man. Arzneimittel-Forschung 27: 1085–1088 (1977).
Levy, R.H.: Monitoring of free valproic acid levels?. Therapeutic Drug Monitoring 2: 199–201 (1980).
Levy, R.H.; Cenraud, B.; Loiseau, P.; Akbaraly, R.; Brachet-Liermain, A.; Guyot, M.; Gomeni, R. and Morselli, P.L.: Meal-dependent absorption of enteric coated sodium valproate. Epilepsia 21: 273–280 (1980).
Levy, R.H.; Lockard, J.S.; Patel, I.H. and Congdon, W.C.: Time-dependent kinetics. III. Diurnal variations in steady state plasma valproic acid levels in rhesus monkeys. Journal of Pharmaceutical Sciences 66: 1154–1156 (1977a).
Levy, R.H.; Lockard, J.S.; Patel, I.H. and Lai, A.A.: Efficacy testing of valproic acid compared to ethosuximide in monkey model. I. Dosage regimen design in the presence of diurnal oscillations. Epilepsia 18: 191–203 (1977b).
Lockard, J.S.; Levy, R.H.; Ducharme, L.L.; Congdon, W.C. and Patel, I.H.: Diurnal variation of valproic acid plasma levels and day/night reversal in the monkey. Epilepsia 18: 183–189 (1977).
Loiseau, P.; Brachet, A. and Henry, P.: Concentration of dipropylacetate in plasma. Epilepsia 11: 609–615 (1975).
Loiseau, P.; Cenraud, B.; Morselli, P.L. and Brachet-Liermain, A.: La biodisponibilité du valproate de sodium est modifiée par l’alimentation. Nouvelle Presse Médicale 8: 2202 (1979).
Marc, V. and Morselli, P.L.: Metabolism of exogenous corrisol in the rat in various experimental conditions. Journal of Pharmacy and Pharmacology 21: 864–866 (1969).
Mattson, R.H.; Cramer, J.A.; Williamson, P.D. and Novelly, R.A.: Valproic acid in epilepsy: Clinical and pharmacological effects. Annals of Neurology 3: 20–25 (1978).
Meijer, J.W.A. and Hessing-Brand, L.: Determination of lower fatty acid, particularly the epileptic dipropylacetic acid in biological materials by means of microdiffusion and gas chromatography. Clinica Chimica Acta 43: 215–222 (1973).
Meijer, J.W.A. and Kalff, R.: Dipropylacetate. Less usual ways of administrating antiepileptic drugs; in Schneider et al (Eds) Clinical Pharmacology of Antiepileptic Drugs, pp.222–228 (Springer-Verlag, Berlin 1975).
Meijer, J.W.A. and Meinardi, H.: Pharmacokinetic studies on sodium valproate; in Legg (Ed.) Clinical and Pharmacological Aspects of Sodium Valproate (Epilim) in the Treatment of Epilepsy pp.70–74 (MCS Consultants, 1975).
Meinardi, H.; Hanke, N.F.J, and Van Beveren, J.: Sodium di-n-propylacetate estimation of effective serum levels. Pharmaceutisch Weekblad 109: 45–47 (1974).
Melander, A.: Influence of food on the bioavailability of drugs. Clinical Pharmacokinetics 2: 337–351 (1978).
Monks, A. and Richens, A.: Serum protein binding of valproic acid and its displacement by palmitic acid in vitro. British Journal of Clinical Pharmacology 8: 187–188 (1979).
Moore-Ede, M.C.: Orcadian rhythms of drug effectiveness and toxicity. Clinical Pharmacology and Therapeutics 14: 925–935 (1974).
Morselli, P.L.; Marc, V.; Garattini, S. and Zaccala, M.: Metabolism of exogenous Cortisol in humans. 1. Diurnal variation in plasma disappearance rate. Biochemical Pharmacology 19: 1643–1647 (1970).
Patel, I.H. and Levy, R.H.: Valproic acid binding to human serum albumin and determination of free fraction in the presence of anticonvulsants and free fatty acids. Epilepsia 20: 85–90 (1979).
Patel, I.H.; Levy, R.H. and Lockard, J.S.: Time-dependent kinetics. II. Diurnal oscillations in steady-state plasma levels of ethosuximide in rhesus monkeys. Journal of Pharmaceutical Sciences 66: 650–653 (1977).
Patel, I.H.; Levy, R.H.; Venkataramanan, R.; Viswanathan, C.T. and Moretti-Ojemann, L.: Diurnal variation in protein binding of valproic acid and Phenytoin and the role of free fatty acids. Clinical Pharmacology and Therapeutics 27(2): 277 (1980).
Rowan, A.J.; Binnie, C.D.; de Beer-Pawlikowski, N.K.B.; Goedhart, D.M.; Gutter, T.; van der Geest, P.; Meinardi, H. and Meijer, J.W.A.: Sodium valproate: Serial monitoring of EEG and serum levels. Neurology 29: 1450–1459 (1979).
Rowan, A.J.; Binnie, C.D.; de Beer-Pawlikowski, N.K.B.; Goedhart, D.M.; Gutter, R.; Van Parys, J.A.P.; Meinardi, H. and Meijer, J.W.A.: 24-hour EEG studies with very frequent serum antiepileptic drug concentration determinations in the study of sodium valproate; in Meinardi and Rowan (Eds) Advances in Epileptology, pp.255–260 (Swets and Zeitlinger 1978).
Rowan, A.J.; Meijer, J.W.A.; Binnie, C.D.; de Beer-Pawlikowski, N.; Gutter, T.; Goedhart, D.; van der Geest, P. and Meinardi, H.: Sodium valproate and sodium valproate-ethosuximide combination therapy: Intensive monitoring studies; in Johan-nessen et al. (Eds) Advances in Antiepileptic Drugs Monitoring, pp. 161–168 (Raven Press, New York 1980).
Schobben, F. and Van Der Kleijn. E.: Determination of sodium di-n-propyl-acetate in plasma by gas-liquid chromatography. Pharmaceutisch Weekblad 109: 30–33 (1974).
Schobben, F.; Van Der Kleijn, E. and Gabreels, F.J.M.: Pharmacokinetics of di-n-propylacetate in epileptic patients. European Journal of Clinical Pharmacology 8: 97–105 (1975).
Schobben, F.; Van Der Kleijn, E.; Vree, T.B. and Guelen, P.J.M.: Pharmacokinetics of dipropylacetate (2-n-propyl-pentanoate) in man and laboratory animals; in Gardner-Thorpe et al. (Eds) Antiepileptic Drug Monitoring pp. 147–164 (Pitman Medical, Tunbridge Wells 1977).
Sonnen, A.E.H.; Blom, G.F. and Meijer, J.W.A.: Enteric-coated dipropylacetate (depakine); in Schneider et al. (Eds) Clinical Pharmacology of Antiepileptic Drugs, pp.229–234 (Springer-Verlag, Berlin 1975).
Welling, P.G.: Influence of food and diet on gastrointestinal drug absorption: A review. Journal of Pharmacokinetics and Bio-pharmaceutics 5: 291–334 (1977).
Wulff, K.; Flachs, H.; Wurtz-Jorgensen, A. and Gram, L.: Clinical pharmacological aspects of valproate sodium. Epilepsia 18: 148–157 (1977).
Zimmerman, C.L.; Patel, I.H.; Levy, R.H.; Edwards, D.; Nelson, S.D. and Hutchinson, M.: Protein binding of valproic acid in the presence of elevated free fatty acids in patient and normal human serum. Epilepsia 22: 11–17 (1981).